Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients
Ontology highlight
ABSTRACT: Objectives:
1. To estimate progression-free survival (PFS) at 12 months in subjects with metastatic colorectal cancer who receive FOLFIRI [folinic acid (leucovorin or LV), 5-Fluorouracil (5-FU), irinotecan) plus bevacizumab as first line treatment.
2. To determine the objective response rate and the duration of objective response in this population.
3. To assess overall survival (OS) in this population.
4. To measure the effect of treatment on intratumoral blood volume and microvascular permeability by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in consenting patients in whom it is technically feasible.
5. To correlate plasma proteomics with response.
6. To assess the safety of this regimen.
DISEASE(S): Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2031080 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA